Lineage Cell Therapeutics, Inc. Deferred Income Tax Liabilities, Net
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Income Tax Liabilities, Net of $22.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Liabilities, Net $22.00K.
- 2026-03-31: Deferred Income Tax Liabilities, Net $22.00K.
- 2025-12-31: Deferred Income Tax Liabilities, Net $22.00K.
- 2025-09-30: Deferred Income Tax Liabilities, Net $273.00K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $22.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $22.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $273.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $273.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $273.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $273.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $273.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $273.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $273.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $273.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $273.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $273.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $273.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.08M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.08M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.08M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.08M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.08M 10-K · filed 2023-03-09 |
| 2021-09-30 | $894.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.91M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $2.08M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $2.08M 10-K · filed 2022-03-10 |
| 2020-09-30 | $3.14M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $3.31M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.31M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $3.31M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |